26 citations
,
June 2011 in “Molecular Medicine” Progesterone significantly reduces neuroblastoma tumor growth without harming healthy cells.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
November 2025 in “Journal of Investigative Dermatology”
July 2011 in “مجله علمی پزوهشی دانشگاه علوم پزشکی ایلام” Testosterone reduces, while finasteride enhances, morphine's pain relief.
7 citations
,
March 2013 in “Tetrahedron Letters” New method makes important drug ingredients more easily without needing extra purification steps.
February 2026 in “Advanced Science” TTNPB helps turn stem cells into neural stem cells, improving depression-like behaviors in rats.
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
40 citations
,
November 2016 in “Molecules” Some plants used in traditional medicine may help treat cancer because they contain proteins that can inactivate ribosomes.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
21 citations
,
May 2016 in “Experimental and Therapeutic Medicine” MMP-2 and MMP-9 help hair grow, while their inhibitors peak when hair growth slows.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” DKK2 and SOSTDC1 together are necessary for the normal timing of the first regression phase in the hair growth cycle.
July 2025 in “International Journal of Biological Macromolecules” The microneedle patch boosts hair growth by reducing DHT and oxidative stress.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tet2 and Tet3 enzymes are essential for controlling hair growth by affecting DNA demethylation and gene expression in mice.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” DNCB is more effective than betamethasone for hair regrowth but has more side effects.
3 citations
,
October 2011 in “JAT. Journal of applied toxicology/Journal of applied toxicology” Doxazosin mesylate and saw palmetto cause genetic changes in fruit flies.
July 2024 in “Natural Product Research” Nk-EE may help treat hair loss by promoting hair growth and preventing hair follicle damage.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
April 2026 in “Research Square”
March 2024 in “Vestnik Rossijskogo universiteta družby narodov. Seriâ Agronomiâ i životnovodstvo” Wnt and Shh signaling are key in noggin-induced tumors, and blocking them can slow tumor growth.
February 2023 in “Medicine in novel technology and devices” Microneedles with traditional Chinese medicine can help regrow hair in androgenic alopecia.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
The new microneedle system safely delivers finasteride through the skin to treat hair loss.
2 citations
,
August 2025 in “Pharmaceutics” PN hydrates skin; PDRN heals and regenerates skin and hair.
Individualized treatments may help manage Dercum's disease symptoms.
1 citations
,
June 2025 in “Cell Biochemistry and Biophysics”
April 2018 in “Journal of Investigative Dermatology” Higher levels of nidogen1 and type IV collagen are found in basal cell carcinoma compared to normal skin.
14 citations
,
February 2024 in “Pharmaceutics” We need to study how dissolving microneedles behave in the body to use them for medicine.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.